Although this literature is nonetheless smaller as a result of the currently limited range of marketed symptomatic therapies, there is no conceptual reason to suspect that one or more of the promising qEEG
and/or ERP markers described above will not be sensitive to change (or a lack thereof), with novel and truly diseasemodifying therapies yet to be discovered.